2018 U.S. sales: $3.6 billion
Used for: fibromyalgia, diabetic nerve pain, spinal cord injury nerve pain, pain after shingles, partial onset seizures
Lyrica's long run as Pfizer’s second-best seller is under threat this year, thanks to impending generic competition in the U.S. But an exclusivity extension it won last year might just keep 2019 sales in blockbuster territory.
Last year, Lyrica secured $3.59 billion in the U.S., a roughly 4% increase year over year for the nerve and muscle pain wonder drug. That boost, driven by price increases, helped Lyrica hold on to its place as Pfizer's second-best seller, but the good times aren't destined to last. With Lyrica's patent set to expire in June, Pfizer expects sales to spiral in the coming years.
Part of Lyrica's latter-day sales hike was fueled by a new approval. Lyrica snagged a label expansion to treat pain caused by shingles or diabetic peripheral neuropathy in October 2017 in a once-daily formulation. That new dosing moved Lyrica away from its original two-to-three-times-daily formulation, which already had a half-dozen approved generic challengers.
Lyrica could continue its strong sales showing for a little longer, thanks to a six-month pediatric exclusivity Pfizer scored last June. That extension is expected to fend off U.S. challengers until the end of June 2019.